Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | NPC1 | O15118 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.73 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.63 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.63 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.63 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.63 |
| ▸ | NQO2 | P16083 | 2/20 | 0.61 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SNCA | P37840 | 1/20 | 0.58 |
| ▸ | TOP1 | P11387 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6557523 | 0.90 | NPC1 (0.77) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL4254150 | 0.88 | MEN1 (0.80) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL4254970 | 0.85 | RAB9A (0.75) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL3089807 | 0.85 | MEN1 (0.75) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL667807 | 0.85 | BCAT2 (0.77) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL3645013 | 0.84 | MEN1 (0.74) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL2696198 | 0.82 | KDM4E (0.74) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL2697884 | 0.82 | KDM4E (0.74) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL6928173 | 0.82 | MEN1 (0.71) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL12190100 | 0.82 | MEN1 (0.71) | MEN1KMT2AKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785499-B2 | Targeting NAD biosynthesis in bacterial pathogens | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785499-B2 | Targeting NAD biosynthesis in bacterial pathogens | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-07-22 | — | — | US | disclosed |
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2057115-B9 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2057115-B1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-07-26 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2057115-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008024746-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | MEN1 4149/4885KMT2A 505/4885KDM4E 1078/4885 |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | NAMPT, NAPRT, NADK | MEN1 2290/4885KMT2A 995/4885KDM4E 1937/4885 |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | MEN1 4149/4885KMT2A 505/4885KDM4E 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.